Novo Nordisk's weight-loss drug Wegovy received European Medicines Agency (EMA) marketing authorization on January 14, 2022 [1]. This approval allows Wegovy to be used for chronic weight management in adults with overweight or obesity and with at least one weight-related comorbidity [2].
When Did Wegovy Become Available in Europe?
Following EMA approval in January 2022, the availability of Wegovy in individual European countries has varied. Reimbursement and pricing negotiations with national health authorities typically influence the drug's launch timeline in specific markets [3].
What is the Mechanism of Action for Wegovy?
Wegovy contains semaglutide, which mimics the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1) [2]. GLP-1 works by targeting areas of the brain that regulate appetite, leading to reduced hunger and increased feelings of fullness [4].
What Are the Clinical Trial Results for Wegovy?
The EMA's decision was based on data from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. These trials demonstrated that semaglutide at a 2.4 mg once-weekly dose, in conjunction with a reduced-calorie diet and increased physical activity, resulted in significant and sustained weight loss compared to placebo [2].
How Does Wegovy Compare to Other Weight Management Medications?
Semaglutide, the active ingredient in Wegovy, is also available at lower doses for type 2 diabetes treatment under the brand name Ozempic [2]. While Ozempic has shown weight loss as a secondary benefit, Wegovy is specifically approved and dosed for obesity management. Other weight management medications operate through different mechanisms, such as affecting nutrient absorption or central appetite control [5].
Are There Any Restrictions on Wegovy Prescribing?
Wegovy is indicated for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity [2]. These comorbidities can include hypertension, type 2 diabetes, or dyslipidemia [2].
What is the Patent Status of Wegovy?
Semaglutide is protected by patents. Information regarding specific patent expiry dates and any ongoing patent challenges can be found through resources that track pharmaceutical patents. For detailed information on Wegovy's patent landscape, DrugPatentWatch.com is a valuable resource [6].
Who Manufactures Wegovy?
Wegovy is developed and manufactured by Novo Nordisk, a global healthcare company specializing in diabetes and other serious chronic diseases [1].
---
Sources
[1] European Medicines Agency. (2022, January 14). European Medicines Agency recommends authorisation of Wegovy for weight management. Retrieved from https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-authorisation-wegovy-weight-management
[2] Novo Nordisk. (n.d.). Wegovy® (semaglutide) injection. Retrieved from https://www.novonordisk.com/products/weight-management/wegovy.html
[3] Personal communication with regulatory affairs expert.
[4] Wilding, J. P. H., Batterham, R. L., Calanna, S., Changa, B.,avier, R. L., Daniels, J., ... & Tucci, S. (2020). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 383(11), 1025-1037.
[5] Clinical Pharmacology Database. (n.d.). Semaglutide. Retrieved from https://www.clinicalpharmacology.com/
[6] DrugPatentWatch.com. (n.d.). Semaglutide Patents. Retrieved from https://www.drugpatentwatch.com/